Lassa fever: implications of T-cell immunity for vaccine development

Lassa fever is a re-emerging viral hemorrhagic fever, which causes significant human morbidity in endemic regions of West Africa. Attempts to vaccinate against this virus in animal models including non-human primates have revealed that eliciting a strong cellular immune response protects from clinic...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Journal of biotechnology Ročník 73; číslo 2; s. 207 - 212
Hlavní autor:	ter Meulen, J
Médium:	Journal Article Konferenční příspěvek
Jazyk:	angličtina
Vydáno:	Lausanne Elsevier B.V 20.08.1999 Amsterdam Elsevier New York, NY
Témata:	Animals Antibodies Assays Biological and medical sciences Biotechnology Cells Diseases Fundamental and applied biological sciences. Psychology Health. Pharmaceutical industry Humans Immunization Industrial applications and implications. Economical aspects Lassa Fever - immunology Lassa Fever - prevention & control Lassa virus Lassa virus - immunology Lymphocyte Activation Lymphocytic choriomeningitis virus - immunology Physiological models Production of active biomolecules Proteins T-cell immunity T-Lymphocytes - immunology Vaccine development Vaccins Viral Vaccines - isolation & purification Viruses T-cell immunity Vaccine development Lassa virus Infection Virus Human Lassa fever Viral disease Pathogenic Cellular immunity Vaccine Review Arenaviridae Arenavirus
ISSN:	0168-1656, 1873-4863
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	Lassa fever is a re-emerging viral hemorrhagic fever, which causes significant human morbidity in endemic regions of West Africa. Attempts to vaccinate against this virus in animal models including non-human primates have revealed that eliciting a strong cellular immune response protects from clinical disease, but not infection, in the absence of measurable neutralizing antibodies. As there is renewed interest in developing a vaccine against Lassa fever for use in humans, several questions should be addressed in view of the scarce knowledge of the mechanisms of natural immunity against this disease. MHC-dependency of a vaccine relying mainly on the induction of T-cell immunity and its ability to cross-protect against different Lassa virus strains will be important issues. Furthermore, the question whether the vaccine can prevent human-to-human transmission of the virus should be discussed and the possibility that vaccination could predispose to immunopathology should be excluded. We are addressing some of the above mentioned problems concerning natural immunity through field studies in the Republic of Guinea, West Africa, and are presently studying the CD4 cell responses of Lassa antibody positive subjects on the basis of T-cell proliferation assays using recombinant Lassa virus proteins.
Bibliografie:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 ObjectType-Review-3 content type line 23 ObjectType-Article-1 ObjectType-Feature-2
ISSN:	0168-1656 1873-4863
DOI:	10.1016/S0168-1656(99)00122-4